drugset / Trial / NCT06222125
A Study of HB0025 Injection in Patients With Advanced Renal Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
It is a phase II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0025 in patients with advanced clear cell renal cell carcinoma (ccRCC).
Timeline
- Start
- 2023-01-30
- Primary completion
- 2025-01-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HB0025 | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | HB0025 | Monoclonal antibody | 20 mg/kg | Intravenous |